Shop All Virus Production Media

OptiPRO™ SFM Gibco™

OptiPRO™ SFM is a serum-free, animal origin-free culture medium designed for growth of several kidney-derived cell lines including MDBK, MDCK, PK-15 and VERO for virus or recombinant protein production. In addition, OptiPRO™ SFM has successfully grown other cell lines, such as Hela, BHK-21 and COS-7. Gibco® OptiPRO™ SFM features:
• Serum-free, animal origin-free, low protein formulation
• Direct adaptation for many popular cell lines

Serum-free, animal origin-free, low protein formulation
Gibco® OptiPRO™ SFM is formulated with a very low protein concentration (< 10 µg/ml), allowing for easier purification of your recombinant protein.

Direct adaptation for many popular cell lines
Gibco® OptiPRO™ SFM has been designed for growth of kidney-derived cell lines such as MDCK, MDBK, VERO and PK-15. In addition, OptiPRO™ SFM has successfully grown other cell lines, such as Hela, BHK-21 and COS-7, allowing you to choose a single medium for multiple cell lines.

Product Use
For Research Use Only. Not for use in diagnostic procedures.

cGMP Manufacturing and Quality System
Gibco® OptiPRO™ SFM is manufactured at a cGMP compliant facility located in Grand Island, New York. The facility is registered with the FDA as a medical device manufacturer and is certified to ISO 13485 standards.

CTS™ LV-MAX™ Production Medium

CTS LV-MAX Production Medium is a chemically-defined, serum-free, protein-free medium validated for recombinant lentiviral vector production. In addition to supporting high cell density suspension cultures of CTS Viral Production Cells (HEK293F-derived cells), this medium is suitable for preclinical-, clinical-, and commercial-scale transient transfection and lentiviral production when used with the CTS LV-MAX Transfection Kit. CTS LV-MAX Production Medium undergoes stringent QC testing to ensure it is appropriate for the manufacturing of cell and gene therapy applications.

CTS LV-MAX Production Medium may be applicable for other recombinant viral vector production that uses a HEK293 medium.

CTS LV-MAX Production Medium features include:
• Supports CTS Viral Production Cells to achieve densities of over 1 x 107 cells/mL with minimal cell clumping
• Enables high viral titers of up to 1 x 108 TU/mL (unconcentrated lentiviral vectors–GFP)
• Scalable protocol for 96-deep well blocks, flasks, and bioreactors
• Regulatory-compliant medium manufactured in conformity with cGMP for medical devices, 21 CFR, Part 820, and certified to the ISO 13485. Drug Master File and Regulatory Support File available upon request.

CTS LV-MAX Production Medium is formulated with GlutaMAX-I reagent. It is ready to use, with no supplementation required. The chemically defined formulation results in high reproducibility and lot-to-lot reliability. The medium contains no human or animal-origin components. It is not recommended for adherent cell cultures. The formulation of this product is identical to research-grade LV-MAX Production Medium, but CTS LV-MAX Production Medium is validated for clinical and commercial therapeutic applications.

Custom configuration and packaging available upon request.

VP-SFM (1X) Gibco™

VP-SFM is a serum-free, ultra-low protein (5 µg/ml) medium containing no proteins, peptides, or other components of animal or human origin. It is designed for the growth of VERO cells for virus production (1). This medium is suitable for the growth of COS-7, MDCK, BHK-21 (suspension culture) and HEp2 cells, and for recombinant protein production.

Formulated without L-glutamine for increased stability; add 20 ml of 200 mM L-glutamine or 20 ml of GlutaMAX™-I supplement per 1,000 ml of medium prior to use.

Adenovirus Expression Medium (AEM), for PER.C6™ cells Gibco™

Adenovirus Expression Medium (AEM) is recommended for the growth of PER.C6® cells in suspension and for the production of viruses and viral vectors in these cells. It is an animal-origin free cell culture medium without components directly derived from human or animal sources. Each lot of AEM is performance tested for cell growth with PER.C6® cells and AEM has been qualified to produce adenovirus and influenza viruses. It also supports HEK 293 cell growth. Glutamine or GlutaMAX™-I supplementation is required.

Diploid Production Serum-Free Medium (SFM) Gibco™

The Gibco Diploid Serum-Reduced Medium (SRM) system is designed to support vaccine manufacture under serum-reduced or serum-free conditions for cell types traditionally cultured in classical media with 10% serum. With this system, human diploid cells, such as MRC-5, Wi38, and KMB17, can be grown with just 1–2% serum. Additionally, it supports growth of chicken embryo fibroblasts under serum-free conditions. Virus production can then be conducted under serum-free conditions without the addition of albumin or other supplements.

The Diploid SRM system is composed of two different kits:
1. Diploid Growth Serum-Reduced Medium (SRM) kit: A basal medium and 100X growth supplement designed for cell expansion
2. Diploid Production Serum-Free Medium (SFM) kit (this page): A basal medium and 100X production supplement designed for virus production

Human cells have traditionally been used to manufacture a variety of vaccines, such as the varicella zoster, polio, smallpox, hepatitis A, measles, mumps, and rubella vaccines. Traditionally, the only way to culture these cells has been to use classical media with 10% serum for growth and 1–5% human albumin (human sourced or recombinant) for virus production. These are two of the highest cost components in vaccine production. The Diploid SRM system helps reduce or eliminate both components while maintaining high virus titers.

Cost savings
Reduction or elimination of serum can significantly reduce cost for a vaccine manufacturing process. Premium FBS is expensive with high price volatility. Given the typical cost pressures on vaccine production, both economic drivers make vaccine manufacturing to a target price extremely challenging. Diploid Growth SRM reduces the impact of this volatility in price and offers a level of cost consistency not available with processes that use serum in high volumes.

In addition, serum requires frozen storage. A 10% serum concentration in growth media can result in high frozen storage requirements for a vaccine process. A process requiring 1,000 L of growth medium would require the frozen storage of 100 L of serum. The Diploid Growth SRM kit comes with a 100X frozen supplement, enabling an 80% reduction in frozen storage requirements. 1,000 L of Diploid Growth SRM would only need 20 L of frozen storage: 10 L for FBS and 10 L for the 100X supplement.

Albumin is commonly added to virus production media. With the Diploid Production SFM, viruses can be produced at comparable titers without any additional supplementation.

No adaptation required
The Diploid SRM system was developed with existing cell banks in mind. Transitioning a vaccine process to a new medium can be challenging due to the need to adapt the cells to the new medium. For human cells such as MRC-5, there is the added risk of reaching the Hayflick limit due to the added passages necessary during cell adaptation and subsequent re-banking of the cells. The transition to the Diploid SRM system does not require adaptation or re-banking of cells when using the Diploid Growth SRM kit. Existing cGMP cells banked with serum may be thawed directly in Diploid Growth SRM supplemented with 1% FBS, allowing a simple transition to this medium.

Mitigate serum supply risk
Obtaining a steady supply of serum can be challenging, especially if the serum required is from a BSE/TSE safe region such as New Zealand or Australia. Serum supply can fluctuate based on several environmental (drought, cattle disease) and economic (feed cost, dairy pricing) factors. With Diploid Growth SRM this dependence is substantially reduced due to the reduced serum requirements.

VP-SFM AGT™ Medium Gibco™

VP-SFM AGT™ is a serum-free, ultra-low protein medium in an easy-to-use granular format. It is designed for the growth of VERO cells for virus production and for the growth of COS-7, MDCK, BHK-21 and Hep-2 cells for recombinant protein production.
Advanced Granulation Technology = AGT

CD BHK-21 Production Medium Gibco™

Gibco® CD BHK-21 Production Medium is a chemically defined, protein-free cell culture medium. It is designed to support the growth of BHK-21 cells in serum-free suspension culture. This medium is suitable for large-scale manufacturing applications.

CD BHK-21 Production Medium is manufactured as follows:
WithWithout
• L-glutamine• Phenol Red
• Dry powder formatProtein hydrolysates

Gibco® CD BHK-21 Production Medium is the first cell culture medium supporting complete serum-free and protein-free processes for BHK-21 cells. The dry powder format is easy to reconstitute, since it has no hydrolysates in the formulation. Adapting cells from serum-containing media is a rapid and simple procedure. BHK-21 cells can achieve high cell densities and maintain high cell viability in this medium.

Gibco® CD BHK-21 Production Medium is suitable for large-scale suspension culture. Because it does not require supplementation with serum or other undefined components, Gibco® CD BHK-21 Production Medium eliminates the risks associated with serum, while allowing you to achieve consistent virus titers and simplifying downstream purification.

cGMP Manufacturing
Gibco® CD BHK-21 Production Medium is manufactured at a cGMP-compliant facility located in Grand Island, New York. The facility is registered with the FDA as a medical device manufacturer and is certified to ISO 13485 standards.

VP-SFM AGT™ Medium Gibco™

VP-SFM AGT™ is a serum free, ultra low protein medium (5 µg/ml) in a new easy-to-use granular format. VP-SFM AGT™ is designed for the growth of VERO cells for virus production. It is also suitable for the growth of COS-7, MDCK, BHK-21 and Hep2 cells and for recombinant protein production.

CD BHK-21 Production Medium Gibco™

Gibco® CD BHK-21 Production Medium is a chemically defined, protein-free cell culture medium. It is designed to support the growth of BHK-21 cells in serum-free suspension culture. This medium is suitable for large-scale manufacturing applications.

CD BHK-21 Production Medium is manufactured as follows:
WithWithout
• L-glutamine• Phenol Red
• Dry powder formatProtein hydrolysates

Gibco® CD BHK-21 Production Medium is the first cell culture medium supporting complete serum-free and protein-free processes for BHK-21 cells. The dry powder format is easy to reconstitute, since it has no hydrolysates in the formulation. Adapting cells from serum-containing media is a rapid and simple procedure. BHK-21 cells can achieve high cell densities and maintain high cell viability in this medium.

Gibco® CD BHK-21 Production Medium is suitable for large-scale suspension culture. Because it does not require supplementation with serum or other undefined components, Gibco® CD BHK-21 Production Medium eliminates the risks associated with serum, while allowing you to achieve consistent virus titers and simplifying downstream purification.

cGMP Manufacturing
Gibco® CD BHK-21 Production Medium is manufactured at a cGMP-compliant facility located in Grand Island, New York. The facility is registered with the FDA as a medical device manufacturer and is certified to ISO 13485 standards.

Diploid Growth Serum-Reduced Medium (SRM) Gibco™

The Gibco Diploid Serum-Reduced Medium (SRM) system is designed to support vaccine manufacture under serum-reduced or serum-free conditions for cell types traditionally cultured in classical media with 10% serum. With this system, human diploid cells, such as MRC-5, Wi38, and KMB17, can be grown with just 1–2% serum. Additionally, it supports growth of chicken embryo fibroblasts under serum-free conditions. Virus production can then be conducted under serum-free conditions without the addition of albumin or other supplements.

The Diploid SRM system is composed of two different kits:
1. Diploid Growth Serum-Reduced Medium (SRM) kit (this page): A basal medium and 100X growth supplement designed for cell expansion
2. Diploid Production Serum-Free Medium (SFM) kit: A basal medium and 100X production supplement designed for virus production

Human cells have traditionally been used to manufacture a variety of vaccines, such as the varicella zoster, polio, smallpox, hepatitis A, measles, mumps, and rubella vaccines. Traditionally, the only way to culture these cells has been to use classical media with 10% serum for growth and 1–5% human albumin (human sourced or recombinant) for virus production. These are two of the highest cost components in vaccine production. The Diploid SRM system helps reduce or eliminate both components while maintaining high virus titers.

Cost savings
Reduction or elimination of serum can significantly reduce cost for a vaccine manufacturing process. Premium FBS is expensive with high price volatility. Given the typical cost pressures on vaccine production, both economic drivers make vaccine manufacturing to a target price extremely challenging. Diploid Growth SRM reduces the impact of this volatility in price and offers a level of cost consistency not available with processes that use serum in high volumes.

In addition, serum requires frozen storage. A 10% serum concentration in growth media can result in high frozen storage requirements for a vaccine process. A process requiring 1,000 L of growth medium would require the frozen storage of 100 L of serum. The Diploid Growth SRM kit comes with a 100X frozen supplement, enabling an 80% reduction in frozen storage requirements. 1,000 L of Diploid Growth SRM would only need 20 L of frozen storage: 10 L for FBS and 10 L for the 100X supplement.

Albumin is commonly added to virus production media. With the Diploid Production SFM, viruses can be produced at comparable titers without any additional supplementation.

No adaptation required
The Diploid SRM system was developed with existing cell banks in mind. Transitioning a vaccine process to a new medium can be challenging due to the need to adapt the cells to the new medium. For human cells such as MRC-5, there is the added risk of reaching the Hayflick limit due to the added passages necessary during cell adaptation and subsequent re-banking of the cells. The transition to the Diploid SRM system does not require adaptation or re-banking of cells when using the Diploid Growth SRM kit. Existing cGMP cells banked with serum may be thawed directly in Diploid Growth SRM supplemented with 1% FBS, allowing a simple transition to this medium.

Mitigate serum supply risk
Obtaining a steady supply of serum can be challenging, especially if the serum required is from a BSE/TSE safe region such as New Zealand or Australia. Serum supply can fluctuate based on several environmental (drought, cattle disease) and economic (feed cost, dairy pricing) factors. With Diploid Growth SRM this dependence is substantially reduced due to the reduced serum requirements.

LV-MAX™ Production Medium Gibco™

Gibco LV-MAX Production Medium is a chemically defined, serum-free, protein-free medium, specially developed for high-density growth and transfection of Gibco Viral Production Cells (suspension-adapted HEK 293-derived cells) promoting high-titer lentiviral production.

• Supports growth of suspension Viral Production Cells to densities of over 1.0 x 107 cells/mL
• Enables sustained, high-level production of high-density transiently transfected cultures, achieving titer of up to 1 x 108 TU/mL (unconcentrated LVVs-GFP)
• Supports growth and transfection of Viral Production Cells in culture formats from 96-deep well blocks to 2-L flasks and bioreactors

LV-MAC Production Medium is ready to use, with no supplementation required. The chemically defined formulation results in high reproducibility and lot-to-lot reliability. The medium is not recommended for adherent cell cultures.

spinner